Connect Biopharma (CNTB) announced it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). On July 16, 2025, the Company received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market that, as of July 15, 2025, the Company’s American Depositary Shares maintained a minimum closing bid price of at least $1.00 for a minimum of 10 consecutive business days. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, the Company’s ADSs will continue to be listed and traded on Nasdaq, and the matter is now closed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Holdings: A Promising Investment with Strategic Drug Developments and Strong Financial Position
- Connect Biopharma’s Partner Submits Drug Application in China
- Connect announces Chinese collaborator submitted NDA for rademikibart
- Connect Biopharma presents data on rademikibart at EAACI
- Connect Biopharma initiated with a Buy at H.C. Wainwright